+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Dalteparin"

From
Lab-synthesized Heparin Market - Global Forecast 2025-2030 - Product Thumbnail Image

Lab-synthesized Heparin Market - Global Forecast 2025-2030

  • Report
  • August 2025
  • 195 Pages
  • Global
From
Thrombosis Drug Market - Global Forecast 2025-2030 - Product Thumbnail Image

Thrombosis Drug Market - Global Forecast 2025-2030

  • Report
  • August 2025
  • 196 Pages
  • Global
From
Heparin Market Report 2025 - Product Thumbnail Image

Heparin Market Report 2025

  • Report
  • September 2025
  • 250 Pages
  • Global
From
Anticoagulants Market Report 2025 - Product Thumbnail Image

Anticoagulants Market Report 2025

  • Report
  • September 2025
  • 250 Pages
  • Global
From
Low Molecular Weight Heparin Market Report 2025 - Product Thumbnail Image

Low Molecular Weight Heparin Market Report 2025

  • Report
  • April 2025
  • 200 Pages
  • Global
From
From
  • 14 Results (Page 1 of 1)
Loading Indicator

Dalteparin is a low molecular weight heparin (LMWH) anticoagulant used to prevent and treat thromboembolic disorders, including deep vein thrombosis (DVT) and pulmonary embolism (PE). It is also used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF). Dalteparin is administered subcutaneously and is available in a variety of dosage forms. Dalteparin is a widely used anticoagulant in the cardiovascular drugs market. It is used to prevent and treat thromboembolic disorders, reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and to reduce the risk of recurrent myocardial infarction. It is also used to reduce the risk of death and recurrent myocardial infarction in patients with acute coronary syndrome. Some companies in the Dalteparin market include Sanofi, Pfizer, Bristol-Myers Squibb, and GlaxoSmithKline. Show Less Read more